Rufinamide
SIGMA/R8404 - ≥98% (HPLC), powder
Synonym: 1-
CAS Number: 106308-44-5
Empirical Formula (Hill Notation): C10H8F2N4O
Molecular Weight: 238.19
MDL Number: MFCD00865314
Linear Formula: C10H8F2N4O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white |
| form | powder |
| InChI | 1S/C10H8F2N4O/c11-7-2-1-3 |
| InChI key | POGQSBRIGCQNEG-UHFFFAOYSA |
| originator | Novartis |
| Quality Level | 100  |
| SMILES string | NC(=O)c1cn(Cc2c(F)cccc2F) |
| solubility | DMSO: 9 mg/mL |
| storage temp. | −20°C |
| Application: | Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model. |
| Biochem/physiol Actions: | Broad-spectrum anticonvulsant. |
| Biochem/physiol Actions: | Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome. |
| Features and Benefits: | This compound was developed by Novartis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| General description: | Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome. |
| Packaging: | 10, 50 mg in glass bottle |
| Symbol |   GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H336 - H351 - H361fd |
| Precautionary statements | P201 - P202 - P261 - P271 - P280 - P308 + P313 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |